Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome
Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/5/918 |
| _version_ | 1797395069755457536 |
|---|---|
| author | Xavier Solanich Miguel Fernández-Huerta Celeste Basaez Arnau Antolí Gemma Rocamora-Blanch Xavier Corbella Miguel Santin Fernando Alcaide |
| author_facet | Xavier Solanich Miguel Fernández-Huerta Celeste Basaez Arnau Antolí Gemma Rocamora-Blanch Xavier Corbella Miguel Santin Fernando Alcaide |
| author_sort | Xavier Solanich |
| collection | DOAJ |
| description | Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; <i>p</i> = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated. |
| first_indexed | 2024-03-09T00:29:03Z |
| format | Article |
| id | doaj.art-11eba06ab2264209aea163cc8905ded9 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T00:29:03Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-11eba06ab2264209aea163cc8905ded92023-12-11T18:37:32ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-0110591810.3390/jcm10050918Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory SyndromeXavier Solanich0Miguel Fernández-Huerta1Celeste Basaez2Arnau Antolí3Gemma Rocamora-Blanch4Xavier Corbella5Miguel Santin6Fernando Alcaide7Department of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, SpainBiochemistry Department, Hospital Interzonal General de Agudos Evita de Lanús, 1826 Lanús, ArgentinaDepartment of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, SpainDepartment of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, SpainDepartment of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, SpainPerformance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; <i>p</i> = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated.https://www.mdpi.com/2077-0383/10/5/918QuantiFERON-TB Gold PlusindeterminateCOVID-19SARS-CoV-2corticosteroids |
| spellingShingle | Xavier Solanich Miguel Fernández-Huerta Celeste Basaez Arnau Antolí Gemma Rocamora-Blanch Xavier Corbella Miguel Santin Fernando Alcaide Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome Journal of Clinical Medicine QuantiFERON-TB Gold Plus indeterminate COVID-19 SARS-CoV-2 corticosteroids |
| title | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
| title_full | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
| title_fullStr | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
| title_full_unstemmed | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
| title_short | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
| title_sort | clinical significance of indeterminate quantiferon tb gold plus assay results in hospitalized covid 19 patients with severe hyperinflammatory syndrome |
| topic | QuantiFERON-TB Gold Plus indeterminate COVID-19 SARS-CoV-2 corticosteroids |
| url | https://www.mdpi.com/2077-0383/10/5/918 |
| work_keys_str_mv | AT xaviersolanich clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT miguelfernandezhuerta clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT celestebasaez clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT arnauantoli clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT gemmarocamorablanch clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT xaviercorbella clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT miguelsantin clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT fernandoalcaide clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome |